[go: up one dir, main page]

MX2022002947A - Avocatina b para el tratamiento de enfermedades y afecciones. - Google Patents

Avocatina b para el tratamiento de enfermedades y afecciones.

Info

Publication number
MX2022002947A
MX2022002947A MX2022002947A MX2022002947A MX2022002947A MX 2022002947 A MX2022002947 A MX 2022002947A MX 2022002947 A MX2022002947 A MX 2022002947A MX 2022002947 A MX2022002947 A MX 2022002947A MX 2022002947 A MX2022002947 A MX 2022002947A
Authority
MX
Mexico
Prior art keywords
avocatin
diseases
treatment
conditions
subject
Prior art date
Application number
MX2022002947A
Other languages
English (en)
Inventor
Paul Anthony Spagnuolo
Nawaz Ahmed
Original Assignee
Sp Nutraceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sp Nutraceuticals Inc filed Critical Sp Nutraceuticals Inc
Publication of MX2022002947A publication Critical patent/MX2022002947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para tratar una enfermedad o afección puede caracterizarse por un trastorno metabólico en un sujeto que lo necesita, que puede incluir la administración al sujeto de una cantidad terapéuticamente efectiva de avocatina B.
MX2022002947A 2019-09-12 2020-09-10 Avocatina b para el tratamiento de enfermedades y afecciones. MX2022002947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962899402P 2019-09-12 2019-09-12
PCT/CA2020/051220 WO2021046646A1 (en) 2019-09-12 2020-09-10 Avocatin b for the treatment of diseases and conditions

Publications (1)

Publication Number Publication Date
MX2022002947A true MX2022002947A (es) 2022-06-14

Family

ID=74867131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002947A MX2022002947A (es) 2019-09-12 2020-09-10 Avocatina b para el tratamiento de enfermedades y afecciones.

Country Status (5)

Country Link
US (1) US12390423B2 (es)
AU (1) AU2020345661B2 (es)
CA (1) CA3150837A1 (es)
MX (1) MX2022002947A (es)
WO (1) WO2021046646A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2798667B1 (fr) 1999-09-22 2001-12-21 Pharmascience Lab Procede d'extraction des composes furaniques et alcools gras polyhydroxyles de l'avocat, composition a base de et utilisation de ces composes en therapeutique, cosmetique et alimentaire
ES2340510T3 (es) 2004-05-28 2010-06-04 Laboratoires Expanscience Uso de alquil-furanos para la preparacion de un medicamento destinado al tratamiento de la obesidad y para el tratamiento cosmetico del exceeso de peso.
US20100305068A1 (en) 2006-11-09 2010-12-02 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
WO2008156654A2 (en) 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
EP2334293A2 (en) 2008-09-08 2011-06-22 Shai Meretzki Compositions comprising polyhydroxyltate fatty alcohol derivatives and the therapeutic uses
PH12013500258B1 (en) 2010-08-09 2019-01-16 Avomex Inc Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds
FR2985666B1 (fr) 2012-01-13 2015-01-09 Expanscience Lab Utilisation de noyau d'avocat pour obtenir une huile d'avocat enrichie en alkyls polyols et/ou en leurs derives acetyles
WO2014009957A1 (en) 2012-07-10 2014-01-16 Polyol Biotech Ltd A process for obtaining polyhydroxylated fatty alcohols from avocado seed and their use in cosmetcs and medicine
WO2016054746A1 (en) 2014-10-09 2016-04-14 Paul Anthony Spagnuolo Avocado-derived lipids for use in treating leukemia

Also Published As

Publication number Publication date
US20230140688A1 (en) 2023-05-04
US12390423B2 (en) 2025-08-19
AU2020345661B2 (en) 2025-07-24
AU2020345661A1 (en) 2022-04-07
CA3150837A1 (en) 2021-03-18
WO2021046646A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
CO2020006009A2 (es) Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos
MX2017005875A (es) Metodos para tratar enfermedades oculares.
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
BR112022000231A2 (pt) Novos métodos
BR112014010803A2 (pt) método de tratamento
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112015022197A2 (pt) tratamento de cataplexia
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
MX2017009694A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.